Users can predict more complex, latent, and immune-related hepatotoxicity in vitro with CN Bio’s PhysioMimix® DILI assay kit: Human 24.
Image Credit: CN Bio Innovations Ltd
The PhysioMimix DILI assay kit has everything you need to recreate CN Bio's FDA-recognized assay in your lab.
The DILI Assay Kit: Human 24 provides critical insights beyond intrinsic DILI predictions, helping you make more informed decisions ahead of in vivo animal and first-in-human studies. This all-in-one kit, combined with CN Bio's PhysioMimix OOC range of Single- and Multi-organ Systems, enables the detection of complex, latent, and immune-related hepatotoxicity events.
The DILI assay kit offers:
Effortless adoption – Quickly start using the most up-to-date Organ-on-a-chip technology with ease
All-in-one kit – Gain direct access to top-quality validated cells and reagents to reliably replicate CN Bio’s PhysioMimix DILI assay
Proven solution – Take advantage of validated protocols, developed through years of experience, strengthened through industry collaboration.
Human relevance – Leverage a human-derived model that facilitates testing for novel drug modalities, with human-specific targets and pathways
Comprehensive support – Enjoy instrument and application support for all parts of the assay
Features of the DILI assay kit
Close the knowledge gap between conventional in vitro and first-in-human research with CN Bio’s PhysioMimix DILI assay kit: Human 24.
- 24-replicate kit: to profile eight conditions in triplicate, including positive and negative controls
- Complement in vivo research: with human in vitro data signals potential interspecies differences and diminishes reliance on animal model data
- Unique Insights: from 3D liver tissues, consisting of primary human hepatocytes and Kupffer cells, over 14 days of culture
- Key metabolic enzyme expression: including CYP enzymes
- Mechanistic profiling: using the large volumes of recoverable tissue and media for longitudinal and endpoint analysis to characterize DILI pathways
- Enhanced clinical translatability: by testing biomarkers, such as ALT/AST, albumin, urea, and LDH
What is in the DILI assay kit: Human 24?
Media. Source: CN Bio Innovations Ltd
| Media |
Volume |
| Liver Basal A Media |
150 mL |
| Liver Basal B Media |
500 mL |
| Thawing Media |
50 mL |
Supplements. Source: CN Bio Innovations Ltd
| Supplements |
Volume |
| Supplement I |
7 x 10 µL |
| Positive Control |
4 x 50 µL |
| Negative Control |
4 x 50 µL |
PhysioMimix plates. Source: CN Bio Innovations Ltd
| Multi-chip plates |
Number of plates/replicates |
| Liver-12+ plates |
2 plates with 24 replicates |
Primary human cells. Source: CN Bio Innovations Ltd
| Primary human cells |
Number of cells |
| Primary Human Hepatocytes |
2 vials |
| Kupffer cells |
2 vials |
Validation report
Browse CN Bio’s sample report that describes the detailed process of validating the primary human hepatocytes and Kupffer cells utilized in the DILI assay kit: Human 24.
The quality control procedures outlined enable you to culture stable, human-relevant liver microtissues that are metabolically active and immune-competent.
Download report
How does CN Bio’s DILI assay kit compare?
Scientists have access to a broad spectrum of preclinical studies and development tools that can be used to assess DILI risks. How does the DILI assay kit, Human 24, compare to more conventional methods?
| |
Liver monolayer / spheroid |
Animal model |
PhysioMimix DILI assay |
| Human |
 |
 |
|
| Human-relevant CYP activity |
|
|
|
| Mechanistic toxicity |
|
|
|
| Advanced drug modalities |
 |
|
 |
| Throughput |
|
|
 |
| Cost |
$ |
$$$ |
$$ |
About CN Bio Innovations Ltd
CN Bio is a leading organ-on-a-chip (OOC) company that offers a portfolio of products and contract research services to optimize the accuracy and efficiency of bringing new medicines to market. With more than a decade of research and development experience, they aim to transform the way human-relevant pre-clinical data is generated through the development of advanced in vitro human organ models.
CN-Bio's PhysioMimix® OOC range of microphysiological systems (MPS) enable researchers to recreate human biology in the lab. This technology bridges the gap between traditional cell culture and human studies, to support the development of safer and more efficacious therapeutics, whilst reducing the dependence on animal model usage.
CN Bio’s portfolio of products (Organ-on-a-chip systems, assay kits, 3D validated cells, consumable plates) and services support researchers that require reliable, data-rich, physiologically relevant, in vitro studies, to uncover novel mechanistic insights into drug or disease mechanism of action.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.